Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Long-Term Debt Repayments (2022 - 2026)

Cytek Biosciences posted quarterly Long-Term Debt Repayments of $869000.0 for Q1 2026, down 42.75% year-on-year from $1.5 million in Q1 2025, and down 70.44% on a QoQ basis from $2.9 million in Q4 2025.

Cytek Biosciences (CTKB) has 5 years of Long-Term Debt Repayments data on file, last reported at $869000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Long-Term Debt Repayments fell 42.75% year-over-year to $869000.0; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 111.57% YoY), and the FY2025 full-year result was $4.7 million, up 751.89% from the prior year.
  • Long-Term Debt Repayments for Q1 2026 stood at $869000.0, down from $2.9 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.9 million in Q4 2025 and bottomed at $50000.0 in Q4 2022.
  • The 5-year median for Long-Term Debt Repayments is $140500.0 (2023), against an average of $484714.3.
  • The widest annual swing landed in 2025, when Long-Term Debt Repayments surged 2015.11%; it then slumped 42.75% in 2026.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $50000.0 in 2022, then surged by 180.0% to $140000.0 in 2023, then dropped by 0.71% to $139000.0 in 2024, then soared by 2015.11% to $2.9 million in 2025, then sank by 70.44% to $869000.0 in 2026.
  • The last three Long-Term Debt Repayments figures came in at $869000.0 (Q1 2026), $2.9 million (Q4 2025), and $145000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Cytek Biosciences - - 21.25 Mn 869,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 869,000.00
Mar 31, 2026 869,000.00
Dec 31, 2025 2.94 Mn
Dec 31, 2025 2.94 Mn
Sep 30, 2025 145,000.00
Sep 30, 2025 145,000.00
Jun 30, 2025 142,000.00
Jun 30, 2025 142,000.00
Mar 31, 2025 1.52 Mn
Mar 31, 2025 1.52 Mn
Dec 31, 2024 139,000.00
Dec 31, 2024 139,000.00
Sep 30, 2024 140,000.00
Sep 30, 2024 140,000.00
Jun 30, 2024 139,000.00
Jun 30, 2024 139,000.00
Mar 31, 2024 139,000.00
Mar 31, 2024 139,000.00
Dec 31, 2023 140,000.00
Dec 31, 2023 140,000.00
Sep 30, 2023 138,000.00
Sep 30, 2023 138,000.00
Jun 30, 2023 141,000.00
Jun 30, 2023 141,000.00
Mar 31, 2023 146,000.00
Mar 31, 2023 146,000.00
Dec 31, 2022 50,000.00
Dec 31, 2022 50,000.00